China and South Korea Reinforce Ties with Renewed MOU on Pharmaceuticals and Cosmetics Regulation
The National Medical Products Administration (NMPA) of China and the Ministry of Food and Drug...
NMPA
ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...
CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
NMPA Seeks Public Comment on Draft Proposal for Drug Re-Registration Procedures
The National Medical Products Administration (NMPA) of China has released a draft proposal for the...
NMPA Updates In Vitro Diagnostic Reagents Classification List for Enhanced Regulatory Oversigh
The National Medical Products Administration (NMPA) has coordinated the revision and release of the In...
Hong Kong SAR and NMPA Renew Agreements to Boost Drug and Medical Device Regulation
Professor Chung-mau LO, BBS, JP, Secretary for Health of the Hong Kong Special Administrative Region...
China Upgrades Midazolam to Category I Psychotropic Drug List in Regulatory Rescheduling
In a joint notification, the National Medical Products Administration (NMPA), Ministry of Public Security, and...
GBA Center of NMPA Launches Filing Guidance for Pharmaceutical Enterprises
The Guangdong-Hong Kong-Macau Greater Bay Area (GBA) Center for Drug Evaluation and Inspection, under the...
China’s NMPA Introduces 12 Measures to Strengthen Drug Operation Administration
The National Medical Products Administration (NMPA) has issued a notification with 12 measures aimed at...
China’s NMPA Releases 79th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) in China has released the 79th batch of reference...
China’s NMPA Launches 2024 Medical Device Industry Standard Revision Plan
The National Medical Products Administration (NMPA) has unveiled the “2024 Medical Device Industry Standard Revision...
NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances
The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...
China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends
The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...
Shanghai Unveils 17 Measures to Enhance Medical Administration Business Environment
Shanghai’s Medical Product Administration has unveiled a comprehensive set of 17 measures aimed at fostering...
NMPA Releases 78th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 78th batch of reference drugs for...
China’s NMPA Updates Rules for Administrative Penalty Discretions in Drug Supervision
The National Medical Products Administration (NMPA) has issued the “Rules for the Application of Administrative...
Fujian Province Issues Provisional Regulations for Managing Medical Representative Visits
The Fujian provincial health commission and medical products administration have jointly issued the “Provisional Regulations...
China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation
The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...
GSK’s Avodart Receives NMPA Approval to Resume Sales in China from September
The National Medical Products Administration (NMPA) has released a notification announcing that GlaxoSmithKline’s (GSK) Avodart...
NMPA Launches Pilot Program to Streamline Supplementary Drug Approval Process
The National Medical Products Administration (NMPA) has unveiled the “Pilot Work Plan for Optimizing the...